Top

Published in:

01-12-2013 | NON-THEMATIC REVIEW

Targeting MAPK pathway in melanoma therapy

Authors: Yabin Cheng, Guohong Zhang, Gang Li

Published in: Cancer and Metastasis Reviews | Issue 3-4/2013

Abstract

New drugs targeting the mitogen-activated protein kinase (MAPK) pathway have generated striking clinical response in melanoma therapy. From the discovery of BRAF mutation in melanoma in 2002, to the approval of first BRAF inhibitor vemurafenib for melanoma treatment by the US Food and Drug Administration in 2011, therapies targeting the MAPK pathway have been proven effective in less than a decade. The success of vemurafenib stimulated more intensive investigation of the molecular mechanisms of melanoma pathogenesis and development of new treatment strategies targeting specific molecules in MAPK pathway. Although selective BRAF inhibitors and MEK inhibitors demonstrated improved overall survival of metastatic melanoma patients, limited duration or development of resistance to BRAF inhibitors have been reported. Patients with metastatic melanoma still face very poor prognosis and lack of clarified therapies. Studies and multiple clinical trials on more potent and selective small molecule inhibitory compounds to further improve the clinical effects and overcome drug resistance are underway. In this review, we analyzed the therapeutic potentials of each member of the MAPK signaling pathway, summarized important MAPK-inhibiting drugs, and discussed the promising combination treatment targeting multiple targets in melanoma therapy, which may overcome the drawbacks of current drugs treatment.

Inamdar, G. S., Madhunapantula, S. V., & Robertson, G. P. (2010). Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochemical Pharmacology, 80(5), 624–637.PubMed

Houghton, A. N., & Polsky, D. (2002). Focus on melanoma. Cancer Cell, 2(4), 275–278.PubMed

Miller, A. J., & Mihm, M. C., Jr. (2006). Melanoma. The New England Journal of Medicine, 355(1), 51–65.PubMed

Balch, C. M., Gershenwald, J. E., Soong, S. J., Thompson, J. F., Atkins, M. B., Byrd, D. R., et al. (2009). Final version of 2009 AJCC melanoma staging and classification. Journal of Clinical Oncology, 27(36), 6199–6206.PubMed

Bedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., et al. (2006). Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. Journal of Clinical Oncology, 24(29), 4738–4745.PubMed

Lui, P., Cashin, R., Machado, M., Hemels, M., Corey-Lisle, P. K., & Einarson, T. R. (2007). Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treatment Reviews, 33(8), 665–680.PubMed

Eggermont, A. M., & Schadendorf, D. (2009). Melanoma and immunotherapy. Hematology/Oncology Clinics of North America, 23(3), 547–564. ix-x.PubMed

Finn, L., Markovic, S. N., & Joseph, R. W. (2012). Therapy for metastatic melanoma: the past, present, and future. BMC Medicine, 10, 23.PubMed

Sharma, A., Tran, M. A., Liang, S., Sharma, A. K., Amin, S., Smith, C. D., et al. (2006). Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Research, 66(16), 8200–8209.PubMed

10.

Panka, D. J., Atkins, M. B., & Mier, J. W. (2006). Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clinical Cancer Research, 12(7 Pt 2), 2371s–2375s.PubMed

11.

Johnson, G. L., & Lapadat, R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298(5600), 1911–1912.PubMed

12.

Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Derijard, B., Davis, R. J., et al. (1994). Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science, 266(5191), 1719–1723.PubMed

13.

Lange-Carter, C. A., & Johnson, G. L. (1994). Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science, 265(5177), 1458–1461.PubMed

14.

Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997). Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. The Journal of Biological Chemistry, 272(7), 4378–4383.PubMed

15.

Mason, C. S., Springer, C. J., Cooper, R. G., Superti-Furga, G., Marshall, C. J., & Marais, R. (1999). Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. The EMBO Journal, 18(8), 2137–2148.PubMed

16.

Aplin, A. E., Stewart, S. A., Assoian, R. K., & Juliano, R. L. (2001). Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. The Journal of Cell Biology, 153(2), 273–282.PubMed

17.

Adachi, T., Kar, S., Wang, M., & Carr, B. I. (2002). Transient and sustained ERK phosphorylation and nuclear translocation in growth control. Journal of Cellular Physiology, 192(2), 151–159.PubMed

18.

Jia, W., Yu, C., Rahmani, M., Krystal, G., Sausville, E. A., Dent, P., et al. (2003). Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood, 102(5), 1824–1832.PubMed

19.

Harada, H., Quearry, B., Ruiz-Vela, A., & Korsmeyer, S. J. (2004). Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proceedings of the National Academy of Sciences of the United States of America, 101(43), 15313–15317.PubMed

20.

Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004). MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene, 23(31), 5301–5315.PubMed

21.

Brazil, D. P., Park, J., & Hemmings, B. A. (2002). PKB binding proteins. Getting in on the Akt. Cell, 111(3), 293–303.PubMed

22.

Cohen, C., Zavala-Pompa, A., Sequeira, J. H., Shoji, M., Sexton, D. G., Cotsonis, G., et al. (2002). Mitogen-actived protein kinase activation is an early event in melanoma progression. Clinical Cancer Research, 8(12), 3728–3733.PubMed

23.

Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., et al. (2003). Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Research, 63(4), 756–759.PubMed

24.

Liu, Z. J., Xiao, M., Balint, K., Smalley, K. S., Brafford, P., Qiu, R., et al. (2006). Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Research, 66(8), 4182–4190.PubMed

25.

Russo, A. E., Torrisi, E., Bevelacqua, Y., Perrotta, R., Libra, M., McCubrey, J. A., et al. (2009). Melanoma: molecular pathogenesis and emerging target therapies (review). International Journal of Oncology, 34(6), 1481–1489.PubMed

26.

Gollob, J. A., Wilhelm, S., Carter, C., & Kelley, S. L. (2006). Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Seminars in Oncology, 33(4), 392–406.PubMed

27.

Klein, R. M., & Aplin, A. E. (2009). Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Research, 69(6), 2224–2233.PubMed

28.

Klein, R. M., Spofford, L. S., Abel, E. V., Ortiz, A., & Aplin, A. E. (2008). B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Molecular Biology of the Cell, 19(2), 498–508.PubMed

29.

Shevde, L. A., & Welch, D. R. (2003). Metastasis suppressor pathways—an evolving paradigm. Cancer Letters, 198(1), 1–20.PubMed

30.

Smalley, K. S. (2003). A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? International Journal of Cancer, 104(5), 527–532.

31.

Govindarajan, B., Bai, X., Cohen, C., Zhong, H., Kilroy, S., Louis, G., et al. (2003). Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. The Journal of Biological Chemistry, 278(11), 9790–9795.PubMed

32.

Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C. N., Sloss, C. M., et al. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Research, 70(13), 5213–5219.PubMed

33.

Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006). The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. The Journal of Experimental Medicine, 203(7), 1651–1656.PubMed

34.

Rajalingam, K., Schreck, R., Rapp, U. R., & Albert, S. (2007). Ras oncogenes and their downstream targets. Biochimica et Biophysica Acta, 1773(8), 1177–1195.PubMed

35.

Wennerberg, K., Rossman, K. L., & Der, C. J. (2005). The Ras superfamily at a glance. Journal of Cell Science, 118(Pt 5), 843–846.PubMed

36.

Omholt, K., Platz, A., Kanter, L., Ringborg, U., & Hansson, J. (2003). NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clinical Cancer Research, 9(17), 6483–6488.PubMed

37.

Zheng, H., Liu, A., Liu, B., Li, M., Yu, H., & Luo, X. (2010). Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. Cancer Letters, 297(1), 117–125.PubMed

38.

Yuan, Y., Hu, H. G., Ye, X. X., Shen, H., & Zheng, S. (2010). K-ras gene mutation in colorectal cancer and its clinicopathologic significance. Zhonghua Wai Ke Za Zhi, 48(16), 1247–1251.PubMed

39.

Lopez-Bergami, P., Fitchman, B., & Ronai, Z. (2008). Understanding signaling cascades in melanoma. Photochemistry and Photobiology, 84(2), 289–306.PubMed

40.

Ackermann, J., Frutschi, M., Kaloulis, K., McKee, T., Trumpp, A., & Beermann, F. (2005). Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Research, 65(10), 4005–4011.PubMed

41.

van 't Veer, L. J., Burgering, B. M., Versteeg, R., Boot, A. J., Ruiter, D. J., Osanto, S., et al. (1989). N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Molecular and Cellular Biology, 9(7), 3114–3116.PubMed

42.

Edlundh-Rose, E., Egyhazi, S., Omholt, K., Mansson-Brahme, E., Platz, A., Hansson, J., et al. (2006). NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Research, 16(6), 471–478.PubMed

43.

Goel, V. K., Lazar, A. J., Warneke, C. L., Redston, M. S., & Haluska, F. G. (2006). Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. The Journal of Investigative Dermatology, 126(1), 154–160.PubMed

44.

Lee, J. H., Choi, J. W., & Kim, Y. S. (2011). Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. The British Journal of Dermatology, 164(4), 776–784.PubMed

45.

Devitt, B., Liu, W., Salemi, R., Wolfe, R., Kelly, J., Tzen, C. Y., et al. (2011). Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell & Melanoma Research, 24(4), 666–672.

46.

Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012). Melanoma: from mutations to medicine. Genes & Development, 26(11), 1131–1155.

47.

Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., & Der, C. J. (1990). Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proceedings of the National Academy of Sciences of the United States of America, 87(8), 3042–3046.PubMed

48.

Dhomen, N., & Marais, R. (2009). BRAF signaling and targeted therapies in melanoma. Hematology/Oncology Clinics of North America, 23(3), 529–545. ix.PubMed

49.

Fensterle, J. (2006). A trip through the signaling pathways of melanoma. Journal der Deutschen Dermatologischen Gesellschaft, 4(3), 205–217.PubMed

50.

End, D. W., Smets, G., Todd, A. V., Applegate, T. L., Fuery, C. J., Angibaud, P., et al. (2001). Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Research, 61(1), 131–137.PubMed

51.

Appels, N. M., Beijnen, J. H., & Schellens, J. H. (2005). Development of farnesyl transferase inhibitors: a review. The Oncologist, 10(8), 565–578.PubMed

52.

Epling-Burnette, P. K., & Loughran, T. P., Jr. (2010). Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. Expert Opinion on Investigational Drugs, 19(5), 689–698.PubMed

53.

Gajewski, T. F., Salama, A. K., Niedzwiecki, D., Johnson, J., Linette, G., Bucher, C., et al. (2012). Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). Journal of Translational Medicine, 10, 246.PubMed

54.

Crul, M., de Klerk, G. J., Swart, M., van't Veer, L. J., de Jong, D., Boerrigter, L., et al. (2002). Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. Journal of Clinical Oncology, 20(11), 2726–2735.PubMed

55.

Punt, C. J., van Maanen, L., Bol, C. J., Seifert, W. F., & Wagener, D. J. (2001). Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anti-Cancer Drugs, 12(3), 193–197.PubMed

56.

Margolin, K. A., Moon, J., Flaherty, L. E., Lao, C. D., Akerley, W. L., 3rd, Othus, M., et al. (2012). Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clinical Cancer Research, 18(4), 1129–1137.PubMed

57.

Field, K. A., Charoenthongtrakul, S., Bishop, J. M., & Refaeli, Y. (2008). Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas. Molecular Cancer, 7, 39.PubMed

58.

Adjei, A. A., Davis, J. N., Bruzek, L. M., Erlichman, C., & Kaufmann, S. H. (2001). Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clinical Cancer Research, 7(5), 1438–1445.PubMed

59.

Basso, A. D., Mirza, A., Liu, G., Long, B. J., Bishop, W. R., & Kirschmeier, P. (2005). The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. The Journal of Biological Chemistry, 280(35), 31101–31108.PubMed

60.

Smalley, K. S., & Eisen, T. G. (2003). Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. International Journal of Cancer, 105(2), 165–175.

61.

Niessner, H., Beck, D., Sinnberg, T., Lasithiotakis, K., Maczey, E., Gogel, J., et al. (2011). The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. The Journal of Investigative Dermatology, 131(2), 468–479.PubMed

62.

Weisz, B., Giehl, K., Gana-Weisz, M., Egozi, Y., Ben-Baruch, G., Marciano, D., et al. (1999). A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene, 18(16), 2579–2588.PubMed

63.

Aharonson, Z., Gana-Weisz, M., Varsano, T., Haklai, R., Marciano, D., & Kloog, Y. (1998). Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochimica et Biophysica Acta, 1406(1), 40–50.PubMed

64.

Kelleher, F. C., & McArthur, G. A. (2012). Targeting NRAS in melanoma. Cancer Journal, 18(2), 132–136.

65.

Jansen, B., Schlagbauer-Wadl, H., Kahr, H., Heere-Ress, E., Mayer, B. X., Eichler, H., et al. (1999). Novel Ras antagonist blocks human melanoma growth. Proceedings of the National Academy of Sciences of the United States of America, 96(24), 14019–14024.PubMed

66.

Smalley, K. S., & Eisen, T. G. (2002). Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. International Journal of Cancer, 98(4), 514–522.

67.

Johnson, M. L., Rizvi, N. A., Ginsberg, M. S., Miller, V. A., Kric, M. G., Pao, W., et al. (2009). A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations Journal of Clinical Oncology, 27 (15 Suppl.), Abstract 8012.

68.

Laheru, D., Rudek, G., Taylor, H., Goldsweig, H., Rajeshkumar. N. V., Linden, S., et al. (2009). Integrated development of s-trans, trans-farnesylthiosalicyclic acid (FTS, salirasib) in advanced pancreatic cancer. Journal of Clinical Oncology, 27 (15 Suppl.), abstract 4529.

69.

Rose, W. C., Lee, F. Y., Fairchild, C. R., Lynch, M., Monticello, T., Kramer, R. A., et al. (2001). Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Research, 61(20), 7507–7517.PubMed

70.

Dinsmore, C. J., Bogusky, M. J., Culberson, J. C., Bergman, J. M., Homnick, C. F., Zartman, C. B., et al. (2001). Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase. Journal of the American Chemical Society, 123(9), 2107–2108.PubMed

71.

Camacho, N. R., Sanchez, J. E., Martin, R. F., Gonzalez, J. R., & Sanchez, J. L. (2001). Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. Journal of the American Academy of Dermatology, 45(5), 697–699.PubMed

72.

Eskandarpour, M., Kiaii, S., Zhu, C., Castro, J., Sakko, A. J., & Hansson, J. (2005). Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. International Journal of Cancer, 115(1), 65–73.

73.

Kloog, Y., Cox, A. D., & Sinensky, M. (1999). Concepts in Ras-directed therapy. Expert Opinion on Investigational Drugs, 8(12), 2121–2140.PubMed

74.

Garnett, M. J., & Marais, R. (2004). Guilty as charged: B-RAF is a human oncogene. Cancer Cell, 6(4), 313–319.PubMed

75.

Mercer, K. E., & Pritchard, C. A. (2003). Raf proteins and cancer: B-Raf is identified as a mutational target. Biochimica et Biophysica Acta, 1653(1), 25–40.PubMed

76.

Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F., & Therrien, M. (2009). A dimerization-dependent mechanism drives RAF catalytic activation. Nature, 461(7263), 542–545.PubMed

77.

Wellbrock, C., Karasarides, M., & Marais, R. (2004). The RAF proteins take centre stage. Nature Reviews Molecular Cell Biology, 5(11), 875–885.PubMed

78.

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949–954.PubMed

79.

Michaloglou, C., Vredeveld, L. C., Mooi, W. J., & Peeper, D. S. (2008). BRAF(E600) in benign and malignant human tumours. Oncogene, 27(7), 877–895.PubMed

80.

Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., et al. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Journal of Clinical Oncology, 29(10), 1239–1246.PubMed

81.

Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., et al. (2003). High frequency of BRAF mutations in nevi. Nature Genetics, 33(1), 19–20.PubMed

82.

Yazdi, A. S., Palmedo, G., Flaig, M. J., Puchta, U., Reckwerth, A., Rutten, A., et al. (2003). Mutations of the BRAF gene in benign and malignant melanocytic lesions. The Journal of Investigative Dermatology, 121(5), 1160–1162.PubMed

83.

Niihori, T., Aoki, Y., Narumi, Y., Neri, G., Cave, H., Verloes, A., et al. (2006). Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nature Genetics, 38(3), 294–296.PubMed

84.

Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S., et al. (2006). Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science, 311(5765), 1287–1290.PubMed

85.

Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 436(7047), 117–122.PubMed

86.

Jane-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., et al. (2010). An oncogenic role for ETV1 in melanoma. Cancer Research, 70(5), 2075–2084.PubMed

87.

Tsao, H., Goel, V., Wu, H., Yang, G., & Haluska, F. G. (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. The Journal of Investigative Dermatology, 122(2), 337–341.PubMed

88.

Patton, E. E., Widlund, H. R., Kutok, J. L., Kopani, K. R., Amatruda, J. F., Murphey, R. D., et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Current Biology, 15(3), 249–254.PubMed

89.

Dhomen, N., Reis-Filho, J. S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., et al. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell, 15(4), 294–303.PubMed

90.

Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky, W. E., Jr., et al. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nature Genetics, 41(5), 544–552.PubMed

91.

Chudnovsky, Y., Adams, A. E., Robbins, P. B., Lin, Q., & Khavari, P. A. (2005). Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nature Genetics, 37(7), 745–749.PubMed

92.

Wu, H., Goel, V., & Haluska, F. G. (2003). PTEN signaling pathways in melanoma. Oncogene, 22(20), 3113–3122.PubMed

93.

Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., et al. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Research, 64(19), 7002–7010.PubMed

94.

Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Research, 63(17), 5198–5202.PubMed

95.

Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., et al. (2004). B-RAF is a therapeutic target in melanoma. Oncogene, 23(37), 6292–6298.PubMed

96.

Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., et al. (2004). V599EB-RAF is an oncogene in melanocytes. Cancer Research, 64(7), 2338–2342.PubMed

97.

Hoeflich, K. P., Gray, D. C., Eby, M. T., Tien, J. Y., Wong, L., Bower, J., et al. (2006). Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Research, 66(2), 999–1006.PubMed

98.

Joseph, E. W., Pratilas, C. A., Poulikakos, P. I., Tadi, M., Wang, W., Taylor, B. S., et al. (2010). The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proceedings of the National Academy of Sciences of the United States of America, 107(33), 14903–14908.PubMed

99.

Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., et al. (2004). BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research, 64(19), 7099–7109.PubMed

100.

Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., et al. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research, 66(24), 11851–11858.PubMed

101.

Kim, S., Yazici, Y. D., Calzada, G., Wang, Z. Y., Younes, M. N., Jasser, S. A., et al. (2007). Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Molecular Cancer Therapeutics, 6(6), 1785–1792.PubMed

102.

Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Research, 65(6), 2412–2421.PubMed

103.

Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., et al. (2006). Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. British Journal of Cancer, 95(5), 581–586.PubMed

104.

Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., et al. (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. Journal of Clinical Oncology, 27(17), 2823–2830.PubMed

105.

Flaherty, K. T., Lee, S. J., Zhao, F., Schuchter, L. M., Flaherty, L., Kefford, R., et al. (2013). Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol, 31(3), 373–379.PubMed

106.

Chapman, P. B., Einhorn, L. H., Meyers, M. L., Saxman, S., Destro, A. N., Panageas, K. S., et al. (1999). Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. Journal of Clinical Oncology, 17(9), 2745–2751.PubMed

107.

Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., et al. (2000). Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of Clinical Oncology, 18(1), 158–166.PubMed

108.

Avril, M. F., Aamdal, S., Grob, J. J., Hauschild, A., Mohr, P., Bonerandi, J. J., et al. (2004). Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. Journal of Clinical Oncology, 22(6), 1118–1125.PubMed

109.

McDermott, D. F., Sosman, J. A., Gonzalez, R., Hodi, F. S., Linette, G. P., Richards, J., et al. (2008). Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. Journal of Clinical Oncology, 26(13), 2178–2185.PubMed

110.

Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., et al. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery, 5(10), 835–844.PubMed

111.

Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., et al. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. The Lancet, 379(9829), 1893–1901.

112.

Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. The Lancet, 380(9839), 358–365.

113.

Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., et al. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. The Lancet Oncology, 13(11), 1087–1095.PubMed

114.

Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 467(7315), 596–599.PubMed

115.

Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., et al. (2012). Vemurafenib: the first drug approved for BRAF-mutant cancer. Nature Reviews. Drug Discovery, 11(11), 873–886.PubMed

116.

Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., Iyer, R., et al. (2010). RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Research, 70(13), 5518–5527.PubMed

117.

Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America, 105(8), 3041–3046.PubMed

118.

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. The New England Journal of Medicine, 363(9), 809–819.PubMed

119.

Ribas, A., & Flaherty, K. T. (2011). BRAF targeted therapy changes the treatment paradigm in melanoma. Nature Reviews Clinical Oncology, 8(7), 426–433.PubMed

120.

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England Journal of Medicine, 364(26), 2507–2516.PubMed

121.

Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., Ariyan, S., et al. (2010). PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell & Melanoma Research, 23(2), 190–200.

122.

Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., et al. (2013). Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature, 494(7436), 251–255.PubMed

123.

Tseng, J. R., Stuart, D., Aardalen, K., Kaplan, A., Aziz, N., Hughes, N. P., et al. (2011). Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor. Neoplasia, 13(3), 266–275.PubMed

124.

Su, Y., Vilgelm, A. E., Kelley, M. C., Hawkins, O. E., Liu, Y., Boyd, K. L., et al. (2012). RAF265 inhibits the growth of advanced human melanoma tumors. Clinical Cancer Research, 18(8), 2184–2198.PubMed

125.

Montagut, C., & Settleman, J. (2009). Targeting the RAF–MEK–ERK pathway in cancer therapy. Cancer Letters, 283(2), 125–134.PubMed

126.

Brower, V. (2010). BRAF inhibitors: research accelerates in wake of positive findings. Journal of the National Cancer Institute, 102(4), 214–215.PubMed

127.

Hoeflich, K. P., Herter, S., Tien, J., Wong, L., Berry, L., Chan, J., et al. (2009). Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Research, 69(7), 3042–3051.PubMed

128.

King, A. J., Patrick, D. R., Batorsky, R. S., Ho, M. L., Do, H. T., Zhang, S. Y., et al. (2006). Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Research, 66(23), 11100–11105.PubMed

129.

Menzies, A. M., Long, G. V., & Murali, R. (2012). Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy, 6, 391–405.PubMed

130.

Eum, K. H., Ahn, S. K., Kang, H., & Lee, M. (2013). Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells. Molecular and Cellular Biochemistry, 372(1–2), 65–74.PubMed

131.

James, J., Ruggeri, B., Armstrong, R. C., Rowbottom, M. W., Jones-Bolin, S., Gunawardane, R. N., et al. (2012). CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Molecular Cancer Therapeutics, 11(4), 930–941.PubMed

132.

Seger, R., Ahn, N. G., Posada, J., Munar, E. S., Jensen, A. M., Cooper, J. A., et al. (1992). Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. The Journal of Biological Chemistry, 267(20), 14373–14381.PubMed

133.

Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., et al. (2012). Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nature Genetics, 44(2), 133–139.

134.

Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology, 29(22), 3085–3096.PubMed

135.

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature, 439(7074), 358–362.PubMed

136.

Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Van Becelaere, K., Wiland, A., Gowan, R. C., et al. (1999). Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Medicine, 5(7), 810–816.PubMed

137.

Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995). PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. The Journal of Biological Chemistry, 270(46), 27489–27494.PubMed

138.

Cross, D. A. E., & Smythe, C. (1998). PD98059 prevents establishment of the spindle assembly checkpoint and inhibits the G(2)-M transition in meiotic but not mitotic cell cycles in Xenopus. Experimental Cell Research, 241(1), 12–22.PubMed

139.

Ge, X., Fu, Y. M., & Meadows, G. G. (2002). U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells. Cancer Letters, 179(2), 133–140.PubMed

140.

Lorusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., et al. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Journal of Clinical Oncology, 23(23), 5281–5293.PubMed

141.

Rinehart, J., Adjei, A. A., Lorusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., et al. (2004). Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. Journal of Clinical Oncology, 22(22), 4456–4462.PubMed

142.

Boasberg, P. D., Redfern, C. H., Daniels, G. A., Bodkin, D., Garrett, C. R., & Ricart, A. D. (2011). Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemotherapy and Pharmacology, 68(2), 547–552.PubMed

143.

Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., et al. (2007). Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clinical Cancer Research, 13(5), 1576–1583.PubMed

144.

Haass, N. K., Sproesser, K., Nguyen, T. K., Contractor, R., Medina, C. A., Nathanson, K. L., et al. (2008). The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clinical Cancer Research, 14(1), 230–239.PubMed

145.

Gopal, Y. N., Deng, W., Woodman, S. E., Komurov, K., Ram, P., Smith, P. D., et al. (2010). Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Research, 70(21), 8736–8747.PubMed

146.

Adjei, A. A., Cohen, R. B., Franklin, W., Morris, C., Wilson, D., Molina, J. R., et al. (2008). Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. Journal of Clinical Oncology, 26(13), 2139–2146.PubMed

147.

Banerji, U., Camidge, D. R., Verheul, H. M., Agarwal, R., Sarker, D., Kaye, S. B., et al. (2010). The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clinical Cancer Research, 16(5), 1613–1623.PubMed

148.

Patel, S. P., & Kim, K. B. (2012). Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. Expert Opinion on Investigational Drugs, 21(4), 531–539.PubMed

149.

Bodoky, G., Timcheva, C., Spigel, D. R., La Stella, P. J., Ciuleanu, T. E., Pover, G., et al. (2012). A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Investigational New Drugs, 30(3), 1216–1223.PubMed

150.

Gilmartin, A. G., Bleam, M. R., Groy, A., Moss, K. G., Minthorn, E. A., Kulkarni, S. G., et al. (2011). GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clinical Cancer Research, 17(5), 989–1000.PubMed

151.

Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., et al. (2012). Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. The Lancet Oncology, 13(8), 773–781.PubMed

152.

Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., DeMarini, D. J., et al. (2012). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. The Lancet Oncology, 13(8), 782–789.PubMed

153.

Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., et al. (2013). Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol, 31(4), 482–489.PubMed

154.

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., et al. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. The New England Journal of Medicine, 367(2), 107–114.PubMed

155.

Finn, R. S., Javle, M. M., Tan Jr, B. R., Weekes, C. C., Bendell, J. C., Patnaik, A., et al. (2012). A phase 1 study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. ASCO Gastrointestinal Cancers Symtosium; Sanfrancisco, CA, USA, Nov 12–16, 2011, abstr 220.

156.

Ascierto, P., Berking, C., Agarwala, S., et al. (2012). Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol, 30, suppl; abstr 8511.

157.

Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., et al. (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. The Lancet Oncology, 14(3), 249–256.PubMed

158.

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. The New England Journal of Medicine, 366(8), 707–714.PubMed

159.

Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., et al. (2008). Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Research, 68(12), 4853–4861.PubMed

160.

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468(7326), 968–972.PubMed

161.

Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 468(7326), 973–977.PubMed

162.

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 480(7377), 387–390.PubMed

163.

Clement, B. (2012). Control of hepatocellular carcinoma progression by the tumor micro-environment. Bulletin de l'Académie Nationale de Médecine, 196(1), 75–84.PubMed

164.

Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 18(6), 683–695.PubMed

165.

Paraiso, K. H., Xiang, Y., Rebecca, V. W., Abel, E. V., Chen, Y. A., Munko, A. C., et al. (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Research, 71(7), 2750–2760.PubMed

166.

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England Journal of Medicine, 367(18), 1694–1703.PubMed

167.

Granville, C. A., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2006). Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clinical Cancer Research, 12(3 Pt 1), 679–689.PubMed

168.

Deng, W., Gopal, Y. N., Scott, A., Chen, G., Woodman, S. E., & Davies, M. A. (2012). Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell & Melanoma Research, 25(2), 248–258.

169.

Davar, D., Tarhini, A. A., & Kirkwood, J. M. (2012). Adjuvant therapy for melanoma. Cancer Journal, 18(2), 192–202.

170.

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363(8), 711–723.PubMed

171.

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine, 364(26), 2517–2526.PubMed

Title: Targeting MAPK pathway in melanoma therapy
Authors: Yabin Cheng
Guohong Zhang
Gang Li
Publication date: 01-12-2013
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 3-4/2013
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-013-9433-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3-4/2013

Erratum to: The role of FOXP3 in the development and metastatic spread of breast cancer

The pre-metastatic niche: finding common ground

Aneuploidy and chromosomal instability: a vicious cycle driving cellular evolution and cancer genome chaos

Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis

Functions, divergence and clinical value of TAp73 isoforms in cancer

Regulation of chromatin structure via histone post-translational modification and the link to carcinogenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer